Design Therapeutics Inc (NASDAQ: DSGN) on Friday, soared 4.34% from the previous trading day, before settling in for the closing price of $5.99. Within the past 52 weeks, DSGN’s price has moved between $2.24 and $7.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 24.37%. With a float of $31.41 million, this company’s outstanding shares have now reached $56.62 million.
The extent of productivity of a business whose workforce counts for 124 workers is very important to gauge. In terms of profitability, gross margin is 48.45%, operating margin of -7256.56%, and the pretax margin is -5701.55%.
Design Therapeutics Inc (DSGN) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Design Therapeutics Inc is 44.53%, while institutional ownership is 41.80%. The most recent insider transaction that took place on Dec 18 ’24, was worth 23,864. In this transaction Director of this company sold 3,806 shares at a rate of $6.27, taking the stock ownership to the 20,000 shares. Before that another transaction happened on Aug 09 ’24, when Company’s Director sold 814,874 for $4.25, making the entire transaction worth $3,463,214. This insider now owns 0 shares in total.
Design Therapeutics Inc (DSGN) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.37% per share during the next fiscal year.
Design Therapeutics Inc (NASDAQ: DSGN) Trading Performance Indicators
Design Therapeutics Inc (DSGN) is currently performing well based on its current performance indicators. A quick ratio of 34.61 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.85, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.21 in one year’s time.
Technical Analysis of Design Therapeutics Inc (DSGN)
The latest stats from [Design Therapeutics Inc, DSGN] show that its last 5-days average volume of 0.33 million was superior to 0.24 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 47.80%. Additionally, its Average True Range was 0.54.
During the past 100 days, Design Therapeutics Inc’s (DSGN) raw stochastic average was set at 60.42%, which indicates a significant increase from 57.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.82% in the past 14 days, which was higher than the 88.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.88, while its 200-day Moving Average is $4.63. Now, the first resistance to watch is $6.47. This is followed by the second major resistance level at $6.68. The third major resistance level sits at $6.99. If the price goes on to break the first support level at $5.95, it is likely to go to the next support level at $5.64. The third support level lies at $5.43 if the price breaches the second support level.
Design Therapeutics Inc (NASDAQ: DSGN) Key Stats
Market capitalization of the company is 369.24 million based on 56,621K outstanding shares. Right now, sales total 0 K and income totals -66,860 K. The company made 0 K in profit during its latest quarter, and -13,040 K in sales during its previous quarter.
